Business Wire

NY-JETBLUE

29.4.2021 19:07:13 CEST | Business Wire | Press release

Share
JetBlue Takes Delivery of First Airbus A321LR Aircraft Enabling Airline to Launch First-Ever Transatlantic Service

JetBlue (NASDAQ: JBLU) today announced it has taken delivery of the airline’s first Airbus A321 Long Range (LR) aircraft, with tail N4022J arriving at JetBlue’s home at John F. Kennedy International Airport (JFK) Terminal 5 this afternoon. This A321LR was assembled at the Airbus production facility in Hamburg, Germany and will enable JetBlue to launch its first-ever transatlantic service between the U.S. and London this summer.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210429005942/en/

“The delivery of our new A321LR sets the stage for a new era at JetBlue in which we now have an aircraft allowing us to stretch our wings and become a true global carrier offering flights beyond the Americas for the first time ever,” said Robin Hayes, chief executive officer, JetBlue. “The A321LR platform – offering the range of a wide-body but with the economics of a single-aisle aircraft – is the right size for us and will allow us to effectively compete with our award-winning service and low fares on flights between the U.S. and London. We congratulate Airbus on bringing to life the most exciting and innovative narrow bodied aircraft cabin in the world and JetBlue is honored to be the launch customer for Airspace on the A320 family.”

The A321LR allows JetBlue to tap into new long-haul markets, like London, that were not previously accessible with the airline’s existing fleet. The LR’s range of up to 4,000 nautical miles is made possible by three additional center fuel tanks and the aircraft delivers 30 percent fuel savings and nearly 50 percent reduction in noise footprint compared to previous generations of aircraft. JetBlue converted 13 aircraft in its existing A321 order book to the LR version in April 2019 with the ability to convert more. Additionally, JetBlue has converted another 13 aircraft in its existing order book to the Extra-Long Range – or XLR – version of the A321.

JetBlue is also the global launch partner for the new Airspace by Airbus cabin, bringing long-haul style to the A321 for the first time ever. Airspace brings a series of enhancements, many customized for JetBlue, including:

  • Stunning backlit ceiling panels through the entire cabin, which glow with a unique-to-JetBlue pattern.
  • Custom LED mood lighting that changes throughout different phases of flight to reduce jetlag technologies.
  • The largest overhead bins on a single-aisle aircraft.
  • New ergonomic sidewalls creating extra personal space at shoulder level.
  • A re-designed welcome area at the front boarding door.
  • Refreshed onboard restrooms with antimicrobial surfaces.

The modern elements of Airspace, combined with the customizations by JetBlue, offer customers a boutique-style setting for the airline’s highly anticipated transatlantic service.

“We are honored that JetBlue is our first launch operator for the new Airspace cabin on Airbus Single-Aisle aircraft. We are also confident that the airline’s customers and crew alike will appreciate the outstanding comfort and in-flight transatlantic experience on board these aircraft,” said Christian Scherer, Airbus Chief Commercial Officer.

JetBlue’s A321LR is powered by two Pratt & Whitney GTF engines. The GTF engine, with its revolutionary geared fan technology, is transforming aviation by delivering game-changing economic and environmental performance. The Pratt & Whitney GTF engine also incorporates advances in aerodynamics, lightweight materials and other major technology improvements.

“Today we celebrate another exciting and historical milestone between Pratt & Whitney and JetBlue,” said Carroll Lane, president of Commercial Engines at Pratt & Whitney. “The GTF-powered Airbus A321LR aircraft will allow JetBlue to fly farther, opening new routes for their customers, while delivering the economic and environmental benefits of our game-changing engine. We look forward to continuing to power their fleet for decades to come.”

Known in the U.S. for having the most legroom in coach (a), live television and on-demand entertainment on every seatback, free Fly-Fi broadband internet (b), complimentary snacks and soft drinks, and great customer service, JetBlue’s entrance into the transatlantic market will introduce a new era of customer-focused, low-fare travel for leisure and business travelers.

The airline’s Mint® premium experience – which first disrupted transcontinental travel in the U.S. and has been completely reimagined for transatlantic flying – promises to offer customers a fresh choice when flying between the U.S. and the U.K. JetBlue Mint features 24 fully lie-flat private suites with a sliding door, a custom-designed seat cushion by Tuft & Needle, and countless design touches that help every customer feel at home in the air. As part of the refresh, JetBlue will also introduce its latest innovation, the stunning Mint Studio™, which will offer the most space in a premium experience from any U.S. airline (c).

JetBlue’s industry-leading core experience has also been reinvented for crossing the pond and will offer a new level of service to customers who want a great experience at a low fare. All of the comforts JetBlue customers have come to expect will be enhanced by the recently announced partnership with Dig to bring its signature build-your-own dining concept to tray tables at 35,000 feet – JetBlue’s first complimentary meal in core. With just 114 core seats, core customers will enjoy a boutique-style experience no matter where they sit.

Customers in both core and Mint will be able to stay connected throughout the flight with the airline’s popular unlimited, free high-speed Wi-Fi. In addition, customers will have access to a curated selection of live TV channels focused on news and sports, and an extensive library of seatback entertainment – allowing customers to have a multiple screen experience onboard, just like they do at home.

Additional details about specific London routes, schedules and out-for-sale dates will be announced soon.

For the latest JetBlue London news visit: https://www.jetblue.com/flying-with-us/london

For more on the JetBlue’s A321LR aircraft visit: https://www.jetblue.com/flying-with-us/our-planes/A321-long-range

About JetBlue Airways

JetBlue is New York's Hometown Airline®, and a leading carrier in Boston, Fort Lauderdale-Hollywood, Los Angeles, Orlando and San Juan. JetBlue carries customers across the U.S., Caribbean and Latin America. For more information, visit jetblue.com .

(a)

 

JetBlue offers the most legroom in coach based on average fleet-wide seat pitch for U.S.

airlines.

 

 

(b)

 

Fly-Fi® and live television are available on all JetBlue-operated flights. Availability and coverage area may vary by aircraft. Details on inflight Wi-Fi and entertainment:

https://www.jetblue.com/flying-with-us/wifi .

 

 

(c)

Based on personal square footage per passenger seat.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye